Acadia Pharmaceuticals | ACAD - Nettoeinkommen





Nettoeinkommen Veränderung Datum
Acadia Pharmaceuticals USD 3.64M 269.93M 2026-03
ALKERMES USD -66.48M 115.82M 2026-03
Alnylam Pharmaceuticals USD 205.99M 19.57M 2026-03
Biogen USD 319.5M 368.4M 2026-03
BioMarin Pharmaceutical USD 105.53M 152.1M 2026-03
Bristol-Myers Squibb USD 2.68B 1.59B 2026-03
Cara Therapeutics USD -5.53M 621K 2025-09
Corcept Therapeutics USD -31.76M 56.05M 2026-03
Cytokinetics USD -206.03M 23M 2026-03
Eisai JPY -3.25B 20.43B 2026-03
Eli Lilly USD 7.4B 760M 2026-03
Incyte USD 303.33M 4.05M 2026-03
J&J USD 5.24B 119M 2026-03
Moderna USD -1.34B 517M 2026-03
Neurocrine Biosciences USD 197.9M 44.2M 2026-03
Pfizer USD 2.69B 4.34B 2026-03
Prothena USD -21.59M 14.95M 2025-12
PTC Therapeutics USD -2.81M 132.16M 2026-03
Sarepta Therapeutics USD 330.96M 743.18M 2026-03
Ultragenyx Pharmaceutical USD -185M 56M 2026-03
Vanda Pharmaceuticals USD -18.9M 13.58M 2024-12
Vertex Pharmaceuticals USD 1.03B 159.7M 2026-03